

# **An high dose of a conjugated linoleic acid increases fatty liver and insulin resistance in lactating mice**

Kun Pang<sup>1</sup>, Song bo Zhu<sup>2</sup>, Liqiang Han<sup>3\*</sup>

<sup>1</sup> College of Animal Science and Veterinary Medicine, Xinyang Agriculture and Forestry University, Xinyang 464006, China

<sup>2</sup> Zhengzhou Academy of agriculture and Forestry Sciences, Zhengzhou 450005, China

<sup>3</sup> College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou 450002, P.R. China

\*Correspondence :Liqiang Han

Short title: a high dose of CLA led to impaired lactation performance

## **Abstract**

This study aimed to evaluate the effect of a high dose of conjugated linoleic acid (CLA) on lactating mice. In experiment one, KUNMING mice were separated into

four groups (n = 6 per group); the control (CON) group received 3.0% linoleic acid oil (LA), the L-CLA group received 1.0% LA and 2.0% CLA mixture, the M-CLA group received 2.0% LA and 1.0% CLA mixture, and the H-CLA group received 3.0% CLA mixture. Feeding proceeded from day 4 to day 10 during lactation. In experiment two, the CON group received 2.0% LA and the H-CLA group received 2.0% CLA. Blood parameters were analysed for all groups, and insulin tolerance tests (ITTs) were conducted. CLA treatment did not affect the dam weight, but it significantly decreased the food intake of dams. Furthermore, CLA decreased the weight of pups, which was attributed to lower milk fat. H-CLA group mice displayed increased liver weight and liver triglyceride content, as well as a higher TG content and  $\gamma$ -GT activity in blood. Moreover, a high dose of CLA resulted in insulin resistance, possibly affecting the RBC and HCB of blood. In conclusion, lactating mice receiving a high dose of CLA led to fatty liver, insulin resistance, and impaired lactation performance.

**Keywords:** mouse; CLA; fatty liver; insulin resistance; lactation

## Introduction

Conjugated linoleic acids (CLAs) are molecules mostly found in meat and dairy products. CLAs have emerged as a possible adjuvant treatment for obesity because

45 some studies show a reduction in body fat and increased lean mass after  
46 supplementation of a mixture of two isomers in the diet [1,2]. CLAs are also reported  
47 to affect carcinogenesis, glucose and lipid metabolism, diabetes, body composition,  
48 and immune cell functions [3-5]. However, certain isomers seem to cause fat  
49 accumulation in the enlarged liver of mice [6], and can induce insulin resistance in  
50 mice and humans [7,8].

51 In humans and other animals, milk lipids are markedly affected by the lipid  
52 composition of the diet, the maternal energy balance, and metabolism. Maternal lipid  
53 intake during lactation can alter milk composition, which in turn can affect the growth  
54 of the litter [9] and change lipid metabolism and liver enzymes [10]. Many previous  
55 studies showed that CLAs can lower triacylglycerol concentrations and alter the fatty  
56 acid profile in the milk of lactating animals including human, mouse, rat, sheep, goat  
57 and cow [11-17]. Feeding lactating mice with CLA can result in diminished  
58 mammary gland lipogenesis and reduced growth rate [18,19], but the exact metabolic  
59 and physiological changes involved remain unclear. More recently, Bezan (2018)  
60 demonstrated that feeding a high dose (3%) of CLA increases insulin resistance and  
61 exacerbates hepatic steatosis in male Wistar rats [20]. The intake of trans-fatty acids  
62 during lactation was also found to increase maternal lipids in the liver (Assumpção,  
63 2004) and liver weight [21]. As indicated above, it is most likely that CLA not only  
64 affects mammary glands during lactation, but also liver and glucose metabolism.

65 CLAs used in supplements originate from the processing of vegetable oils such  
66 as Safflower oil, and always include an equimolar mixture of c9,t11-CLA and

t10,c-12-CLA. Most studies of CLAs have used a mixture of isomers, with c9,t11-CLA and t10,c-12-CLA the most abundant [20,22]. To explore this further, two experiments were performed in which mice were fed with a CLA mixture. Firstly, the effects of different doses of the CLA mixture on the milk and liver of dams was investigated. Secondly, we tested whether a high dose of CLA could cause insulin resistance in dams.

73

## 74 **Materials and Methods**

### 75 **Diets and feeding**

76 Kunming (KM) mice were approved for use in this study by the University of  
77 Zhengzhou for Medical Sciences Animal Care and Use Committee. Animals were  
78 housed at 24°C with 40% humidity and a 12/12 h light-dark cycle. Animals were  
79 provided with food and water random. A mouse-breeder diet (Laboratory Animal  
80 Central, Henan province, China) containing the required complement of nutrients for  
81 lactation was used as a carrier for each of the four fatty acid treatments. The fatty acid  
82 composition of CLA oil and LA oil is shown in Table 1. Diets were prepared the day  
83 before parturition and stored at 4°C.

84 In experiment one, all dams were fed the laboratory chow diet for the first 3 days  
85 of lactation. On day 4 postpartum, six lactating mice were randomly assigned to the  
86 control group (CON group, 3.0% LA oil), the low level CLA group (L-CLA group,  
87 1.0% CLA + 2.0% LA), the median level CLA group (M-CLA group, 2.0% CLA +  
88 1.0% LA), and the high level CLA group (H-CLA group, 3.0% CLA) from day 4 to

10 postpartum. The litter number was normalised to eight at postpartum. Dam weight, food intake, and the eight pups weight were determined daily between days 4 to 10 postpartum. The accurate assessment of food intake was achieved by accurately collecting spilled food from cages. Based on the previous day's intake, a sufficient amount of feed was offered to ensure at least 10% refusal. On day 10 postpartum, pups were separated from dams for 2 h before feeding to ensure maximal accumulation of milk in the mammary gland. Subsequently, all dams were milked by suction. Pups were killed by cervical dislocation, and their abdomens were opened and milk clots within the stomach were weighed and stored at -78°C until analysis [12,23]. The milk lipid concentration was measured gravimetrically after chloroform-methanol extraction by a modified Folch method [24]. Protein concentration was determined by the Biuret method with casein as a standard. The milk lactose concentration was estimated by Cocciardi method [25]. Dams were killed on day 10 of lactation. Mammary and liver tissue from lactating mice was excised and weighed, frozen in liquid nitrogen, and stored at -80°C. Triglycerides in liver were extracted and analysed using a Tissue Triglyceride Assay Kit (E1013, Applygen Technologies Inc) according to the manufacturer's protocol.

In experiment two, dams received 3.0% LA oil (CON group) or 3.0% CLA oil (H-CLA group) from day 4 to day 10 of lactation. Feeding conditions were the same as in the first experiment. Blood was collected from dams and analysed in the First Affiliated Hospital of Zhengzhou University. Plasma insulin concentrations were quantified using a Mouse Insulin Ultra-sensitive ELISA Kit (BC1710, Solarbio). For

ITTs, on the 11th day of lactation, all pads were renewed, and dams were starved for 6 h and weighed. Each dam was intraperitoneally injected with insulin (Novolin) at a dose of 0.75 U/kg body weight. Before injection, the baseline blood glucose concentration was measured and recorded as 0 min. After injection of insulin, the blood glucose level in the tail vein was measured at 15, 30, 60, 90 and 120 min using a TIDEX glucose analyser (Sankyo, Tokyo). The rate constant for each ITT (KITT) was calculated using the equation  $KITT (\%/min) = 0.693 / t(1/2)$ , where  $t(1/2)$  was calculated from the slope of plasma glucose concentration during 15–90 min after administration of intravenous insulin.

## Statistical analysis

Results are reported as mean  $\pm$  standard deviation (SD). Data statistics and differences among groups were analysed by SPSS 13.0 (IBM, USA). All experiments were conducted in triplicate and repeated at least twice. Data were analysed for significant differences using a general linear model of repeated measures, one-way analysis of variance (ANOVA), or Student's t-tests. A  $p$ -value  $<0.05$  was considered statistically significant.

## Results

### Dam body weight and food intake

Dam body weight increased progressively, and revealed a linear effect over time ( $p <0.01$ , Fig. 1A), but there were no significant differences between different treatment groups. Significant effects of treatment and time were observed for food

intake of dams ( $p < 0.05$ , Fig. 1B). Within the CLA treatment groups, there was a significant difference in food intake between the L-CLA and M-CLA groups, and the H-CLA group.

### **Pup body weight**

The eight pups weight was measured daily and the results are shown in Fig. 2. Significant effects for both both time and treatment were observed for pup weight gain over the feeding period. Although the pup weight in all four groups increased from day 4 to day 10, pups in the H-CLA group grew more slowly, and at the end of the study, the eight pup weight of the H-CLA group was significantly lower than that of the other groups (39.38 vs. 54.47, 54.95, and 51.13,  $p < 0.01$ ) by day 10 of lactation.

### **Milk and liver**

The milk clot weight obtained from the stomach ranged between 0.91 g and 0.56 g/suckling pup. The milk fat content of the H-CLA group was significantly lower than that of the other groups. There were no significant differences in protein and lactose concentrations in milk between CLA and control groups (Table 2). Similarly, there were no differences in the weight of mammary tissue between these groups. Liver weight was increased gradually with increasing dose of CLA, and there was a significantly higher TG content in the liver of H-CLA group mice compared with other groups (Table 2).

### **Blood metabolite analysis**

Similar to experiment one, in experiment two, the weight of pups in the high

dose CLA group was significantly lower than that in the control group (Fig. 3). CHO, HDL and LDL levels in serum were unaffected, but plasma T and  $\gamma$ -GT activity in the H-CLA treatment group were higher than in the control group ( $p < 0.05$ ), and glucose was also increased ( $p = 0.07$ , Table 3). Insulin activity was significantly higher in the H-CLA group. Interestingly, CLA feeding resulted in higher RBC and HGB values in the blood of mice in the H-CLA group.

### **Insulin tolerance testing**

At 0 min, the blood glucose level in the control group was 6.62 mmol/L, and that of the CLA group was 7.04 mmol/L (Fig. 3). After injection of insulin, glucose in the control group decreased to 4.03 mmol/L at 90 min, while glucose levels in the H-CLA group were not obviously decreased (6.08 mmol/L). As shown by the decrease in KITT, feeding mice with an high dose of CLA resulted in a significant insulin resistance state.

### **Discussion**

CLA can reduce fat deposition, weight gain, and food/energy intake in mice [26]. In our present study, CLA treatment decreased food intake but did not reduce dam weight. Although the mechanism is not clear, it is likely related to the lactation stage, since mammary glands are the most active lipid-secreting organ in lactating mice [27]. Chin (1994) reported that increased maternal intake of CLA during lactation enhanced the growth rate of suckling neonatal rats [28]. In contrast to the stimulatory effect of CLA, mixtures of CLA [19] or isoforms [18] caused litter pups to grow



slowly or even die due to decreased milk fat. These contradictory results might be due to differences in the content or isomeric distribution of the CLA supplement. In our present study, 2% CLA diet fed to KM mice during lactation decreased both milk weight and milk fat content. Milk is the only source of nutrients for suckling pups; hence it was not surprising that a reduction in the fat and weight of milk were accompanied by reduced pup weight during lactation. These results are consistent with those of other studies on mice [12]. These findings confirmed that a high dose of CLA lowered the content of milk fat and pup growth rate.

CLA has been reported to generate fatty liver, which could be a consequence of increased lipogenesis in the liver to compensate the reduction in fat deposition in adipose tissue [26]. We assessed the liver of dams and observed increased liver weight and TG content in mice given a high dose of CLA. Kadegowda (2010) reported that mice treated with CLA displayed decreased milk fat and increased liver weight due to hepatic steatosis [29], similar to our current results. The effects of CLA supplementation on mammary fat synthesis have received a great deal of attention [30,31], but the potentially adverse effects of CLA on the liver and lipid metabolism have been largely ignored in lactating animals. We suggest that severe lipid accumulation occurs in the liver when lactating mice are given a high dose of CLA. This was also confirmed by increased TG content and  $\gamma$ -glutamyl-transferase ( $\gamma$ -GT) activity in the serum of the high CLA group.

There have been many reports regarding CLA causing insulin resistance [7]. In the present study, ITTs clearly indicated that a high dose of CLA fed to mice caused

insulin resistance. In lactating mice, glucose is the main precursor for the synthesis of lactose and triglyceride substrates. During the lactation stage, mammary glands have increased demand for glucose, and are highly sensitive to insulin, while other organs are relatively insensitive to insulin [32]. In this study, lactating mice fed with CLA displayed aggravated insensitivity to insulin and exhibited insulin resistance, implicating insulin as a key factor in CLA-mediated regulation of milk fat and lactation.

Interesting, we observed for the first time that a high dose of CLA can result in higher RBC and HGB levels in the blood of lactating mice. RBC and HGB are both positively correlated with insulin resistance and NAFLD [33]. Thus, in the present study, higher RBC and HGB may be a consequence of insulin resistance and fatty liver in mice receiving an high dose of CLA.

In summary, a high level of CLA ingestion during lactation decreases milk fat and increases lipid content in the liver. Therefore, CLA is a dietary factor with a propensity to affect hepatic metabolism during lactation. Little is known about the metabolic changes in animals during lactation, especially the possibility of a very complex regulatory mechanism between lipid metabolism in the liver and mammary lactation. The present findings provide a platform for further studies on the exact mechanism and the safe use of CLA .

# **Conflict of Interest**

The authors declare no competing financial interests.



## References

1. West DB, Delany JP, Camet PM, Blohm F, Truett AA, et al. (1998) Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. *Am J Physiol* 275: R667-672.
2. Scalerandi MV, Gonzalez MA, Sain J, Farina AC, Bernal CA (2014) Effect of conjugated linoleic acid mixtures and different edible oils in body composition and lipid regulation in mice. *Nutr Hosp* 29: 591-601.
3. Belury MA (2002) Dietary conjugated linoleic acid in health: Physiological effects and mechanisms of action. *Annual Review Of Nutrition* 22: 505-531.
4. Lee KW, Lee HJ, Cho HY, Kim YJ (2005) Role of the conjugated linoleic acid in the prevention of cancer. *Critical Reviews In Food Science And Nutrition* 45: 135-144.
5. Bhattacharya A, Banu J, Rahman M, Causey J, Fernandes G (2006) Biological effects of conjugated linoleic acids in health and disease. *Journal Of Nutritional Biochemistry* 17: 789-810.
6. Clement L, Poirier H, Niot I, Bocher V, Guerre-Millo M, et al. (2002) Dietary trans-10,cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. *Journal Of Lipid Research* 43: 1400-1409.
7. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, Kim HJ, Tange T, et al. (2000) Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. *Diabetes* 49: 1534-1542.
8. Riserus U, Arner P, Brismar K, Vessby B (2002) Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. *Diabetes Care* 25: 1516-1521.
9. Del Prado M, Delgado G, Villalpando S (1997) Maternal lipid intake during pregnancy and lactation alters milk composition and production and litter growth in rats. *J Nutr* 127: 458-462.
10. Chapman C, Morgan LM, Murphy MC (2000) Maternal and early dietary fatty acid intake: changes in lipid metabolism and liver enzymes in adult rats. *J Nutr* 130: 146-151.
11. Masters N, McGuire MA, Beerman KA, Dasgupta N, McGuire MK (2002) Maternal supplementation with CLA decreases milk fat in humans. *Lipids* 37: 133-138.
12. Harvatin KJ, Robblee MM, Thorn SR, Boisclair YR, Bauman DE (2014) Trans-10, cis-12 CLA Dose-Dependently Inhibits Milk Fat Synthesis without Disruption of Lactation in C57BL/6J Mice. *Journal Of Nutrition* 144: 1928-1934.
13. Assumpcao RP, dos Santos FD, Andrade PDM, Barreto GF, do Carmo MDT (2004) Effect of variation of trans-fatty acid in lactating rats' diet on lipoprotein lipase activity in mammary gland, liver, and adipose tissue. *Nutrition* 20: 806-811.
14. Lock AL, Teles BM, Perfield JW, Bauman DE, Sinclair LA (2006) A conjugated linoleic acid supplement containing trans-10, cis-12 reduces milk fat synthesis in lactating sheep. *Journal Of Dairy Science* 89: 1525-1532.
15. Lock AL, Rovai M, Gipson TA, de Veth MJ, Bauman DE (2008) A conjugated linoleic acid supplement containing trans-10, cis-12 conjugated linoleic acid reduces milk fat synthesis in lactating goats. *Journal Of Dairy Science* 91: 3291-3299.
16. Perfield JW, 2nd, Lock AL, Griinari JM, Saebo A, Delmonte P, et al. (2007) Trans-9, cis-11 conjugated linoleic acid reduces milk fat synthesis in lactating dairy cows. *J Dairy Sci* 90: 2211-2218.
17. Hayashi AA, de Medeiros SR, Carvalho MH, Lanna DPD (2007) Conjugated linoleic acid (CLA)

265 effects on pups growth, milk composition and lipogenic enzymes in lactating rats. *Journal Of*  
266 *Dairy Research* 74: 160-166.

267 18. Looor JJ, Lin XB, Herbein JH (2003) Effects of dietary cis 9, trans 11-18 : 2, trans 10, cis 12-18 : 2  
268 or vaccenic acid (trans 11-18 : 1) during lactation on body composition, tissue fatty acid  
269 profiles, and litter growth in mice. *British Journal Of Nutrition* 90: 1039-1048.

270 19. Ringseis R, Saal D, Muller A, Steinhart H, Eder K (2004) Dietary conjugated linoleic acids lower  
271 the triacylglycerol concentration in the milk of lactating rats and impair the growth and  
272 increase the mortality of their suckling pups. *J Nutr* 134: 3327-3334.

273 20. Bezan PN, Holland H, de Castro GS, Cardoso JFR, Ovidio PP, et al. (2018) High Dose of A  
274 Conjugated Linoleic Acid Mixture Increases Insulin Resistance in Rats Fed Either A Low Fat  
275 or A High Fat Diet. *Experimental And Clinical Endocrinology & Diabetes* 126: 379-386.

276 21. Vyas D, Teter BB, Delmonte P, Erdman RA (2014) Rosiglitazone, a PPAR-gamma Agonist, Fails  
277 to Attenuate CLA-Induced Milk Fat Depression and Hepatic Lipid Accumulation in Lactating  
278 Mice. *Lipids* 49: 641-653.

279 22. Zabala A, Portillo MP, Macarulla MT, Rodriguez VM, Fernandez-Quintela A (2006) Effects of  
280 cis-9, trans-11 and trans-10, cis-12 CLA isomers on liver and adipose tissue fatty acid profile  
281 in hamsters. *Lipids* 41: 993-1001.

282 23. Yang L, Yeung SYV, Huang Y, Wang HQ, Chen ZY (2002) Preferential incorporation of trans,  
283 trans-conjugated linoleic acid isomers into the liver of suckling rats. *British Journal Of*  
284 *Nutrition* 87: 253-260.

285 24. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of  
286 total lipides from animal tissues. *J Biol Chem* 226: 497-509.

287 25. Cocciardi RA, Ismail AA, van de Voort FR, Sedman J (2002) A rapid Fourier transform infrared  
288 quality control method for the determination of lactose, sucrose, fat and total solids in  
289 chocolate milk. *Milchwissenschaft-Milk Science International* 57: 90-93.

290 26. Wang YW, Jones PJH (2004) Conjugated linoleic acid and obesity control: efficacy and  
291 mechanisms. *International Journal Of Obesity* 28: 941-955.

292 27. Schwertfeger KL, McManaman JL, Palmer CA, Neville MC, Anderson SM (2003) Expression of  
293 constitutively activated Akt in the mammary gland leads to excess lipid synthesis during  
294 pregnancy and lactation. *J Lipid Res* 44: 1100-1112.

295 28. Chin SF, Storkson JM, Albright KJ, Cook ME, Pariza MW (1994) Conjugated linoleic acid is a  
296 growth factor for rats as shown by enhanced weight gain and improved feed efficiency. *J Nutr*  
297 124: 2344-2349.

298 29. Kadegowda AKG, Connor EE, Teter BB, Sampugna J, Delmonte P, et al. (2010) Dietary trans  
299 Fatty Acid Isomers Differ in Their Effects on Mammary Lipid Metabolism As Well As  
300 Lipogenic Gene Expression in Lactating Mice. *Journal Of Nutrition* 140: 919-924.

301 30. Sandri EC, Camera M, Sandri EM, Harvatine KJ, De Oliveira DE (2018) Peroxisome  
302 proliferator-activated receptor gamma (PPAR gamma) agonist fails to overcome trans-10,  
303 cis-12 conjugated linoleic acid (CLA) inhibition of milk fat in dairy sheep. *Animal* 12:  
304 1405-1412.

305 31. Urrutia NL, Toledo M, Baldin M, Ford JL, Green MH, et al. (2018) Kinetics of trans-10,  
306 cis-12-conjugated linoleic acid transfer to plasma and milk following an abomasal bolus in  
307 lactating dairy cows. *British Journal Of Nutrition* 120: 259-268.

308 32. Burnol AF, Leturque A, Ferre P, Girard J (1983) Glucose metabolism during lactation in the rat:

quantitative and regulatory aspects. Am J Physiol 245: E351-358.  
33. Jiang YZ, Zeng J, Chen B (2014) Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. Journal Of Gastroenterology And Hepatology 29: 1508-1514.

**Table 1 composition of LA oil and CLA oil**

Composition	CLA (%)	LA (%)
Palmitic acid (C16: 0)	4.89	3.58
Stearic acid (C18: 0)	2.15	1.26
Oleic acid (C18: 1)	10.64	11.21
Linoleic acid (C18: 2)	0.75	80.13
Conjugated Linoleic acid (C18: 2)	81.48	-
c9,t11 CLA	37.53	-
t10,c12 CLA	38.38	-
Others CLA	5.57	-
Linolenic acid (C18: 3)	0	2.35
Others fatty acid	0.09	1.47

**Table 2 Effect of CLA on the milk and liver of dams**

	CON group <sup>#</sup>	L-CLA group	M-CLA group	H-CLA group
Milk clotweight (g/pup )	0.89±0.27 <sup>a</sup>	0.91±0.12 <sup>a</sup>	0.85±0.23 <sup>a</sup>	0.56±0.29 <sup>b</sup>
Milk fat (mg/100mg)	15.42±1.43 <sup>a</sup>	14.16±1.96 <sup>a</sup>	13.37±2.30 <sup>a</sup>	11.88±1.99 <sup>b</sup>
Milk protein (mg/100mg)	18.79±1.35	20.19±2.30	17.96±3.71	19.87±3.32
Milk lactose (mg/100mg)	2.03±0.56	1.89±1.45	2.26±0.85	1.93±1.30
Mammary Weights (g)	3.88±0.69	4.21±0.79	4.39±1.23	3.96±1.06
liver Weights (g)	2.91±0.29 <sup>a</sup>	3.02±0.41 <sup>a</sup>	3.63±0.55 <sup>ab</sup>	4.65±0.59 <sup>b</sup>
TG of liver (mg/g tissue)	46.41±27.07 <sup>a</sup>	94.51±32.78 <sup>ab</sup>	92.5±34.16 <sup>ab</sup>	230.14±80.54 <sup>b</sup>

<sup>a,b</sup>Values followed by different letters in the same row indicate significant differences

( $p < 0.05$ ). Values are means  $\pm$  SD.

#CON group, 342.0% LA oil; L-CLA group, 1.0% CLA + 2.0% LA; M-CLA group, 2.0% CLA + 1.0% LA; H-CLA group, 3.0% CLA.

**Table 3 Effect of a high dose of CLA on the blood of dams**

Parameters	CON group <sup>#</sup>	H-CLA group	P-values
CHO (mmol/L)	2.52±0.38	2.86±1.01	0.461
TG (mmol/L)	1.04±0.34	2.17±1.26	0.044

HDL (mmol/L)	1.53±0.21	1.56±0.46	0.887
LDL (mmol/L)	0.22±0.08	0.29±0.05	0.162
Glucose (mmol/L)	6.58±1.20	7.49±1.53	0.070
ALT (U/L)	39.2±10.51	41±27.38	0.896
AST (U/L)	69.4±13.97	74.16±7.28	0.560
γ-GT (U/L)	15.4±3.92	24.5±2.98	0.005
ALP (U/L)	22±8.02	28.5±2.29	0.183
Insulin (ng/ml)	6.38±1.72	27.15±4.91	<0.001
WBC(10 <sup>9</sup> /L)	3.31±1.74	2.94±1.28	0.734
RBC(10 <sup>12</sup> /L)	7.35±0.47	8.66±0.34	0.002
PLT (10 <sup>9</sup> /L)	1415.83±84.93	1326±196.74	0.431
HGB(g/L)	117±8.10	140±4.04	0.002


337 # CON group, 3.0% LA oil; H-CLA group, 3.0% CLA oil.

338


339

340







**Figure 1**



**Figure 2**



**Figure 3**



**Figure 4**

## Figure Legends

**Figure 1.** Daily body weight and food intake of dams fed different doses of CLA.

Values are means  $\pm$  SD (n = 6). (A) Dam body weight during day 4 to day 10 of lactation. (B) Food intake during day 4 to day 10 of lactation. CON group, 342.0% LA oil; L-CLA group, 1.0% CLA + 2.0% LA; M-CLA group, 2.0% CLA + 1.0% LA; H-CLA group, 3.0% CLA; T, effect of CLA treatment. D $\times$ T, time and treatment interaction.

**Figure 2.** Daily weight of nursing pups fed different doses of CLA during day 4 to

day 10 of lactation. Values are means  $\pm$  SD (n = 6). CON group, 342.0% LA oil; L-CLA group, 1.0% CLA + 2.0% LA; M-CLA group, 2.0% CLA + 1.0% LA; H-CLA group, 3.0% CLA; D, effect of lactation time, T, effect of CLA treatment; D $\times$ T, time and treatment interaction.

**Figure 3.** Dams and eight pups of CON and H-CLA groups in experiment two at day 10 of lactation.

**Figure 4.** Insulin tolerance tests (ITTs) of lactating mice in CON and H-CLA groups.

Values are means  $\pm$  SD (n = 6). (A) ITTs of lactating mice. Each dam was injected with insulin at a dose of 0.75 U/kg body weight. Blood glucose level was measured at 0, 15, 30, 60, 90 and 120 min. (B) Calculation of KITT (%min) after a dose of 0.75 U of insulin per kg of body weight. CON group, 2.0% LA oil; H-CLA group, 2.0% CLA;

401     **\*\*** $p < 0.01$ .

402